Crexont, an extended-release formulation of levodopa and carbidopa, is now available in pharmacies across the U.S. for people with Parkinson’s disease. The Parkinson’s therapy, marketed by Amneal Pharmaceuticals is designed to maintain steady levels of levodopa and carbidopa in the body, extending periods of optimal symptom management,…
A National Institutes of Health (NIH) grant will fund the creation of a brain-on-a-chip technology, a microengineered device containing nerve cells and blood vessels to help scientists more fully understand how neurodegenerative diseases like Parkinson’s and Lewy body dementia affect their ability to function. Jungwook Paek, PhD,…
SGLT2 inhibitors, which are a type of medication to treat diabetes, may reduce the risk for neurodegenerative conditions, including Parkinson’s disease and dementia, a study from South Korea suggests. The overall risk for developing dementia due to any cause and Parkinson’s was lower in patients taking SGLT2 inhibitors than…
Ten consecutive weeks of either high-intensity interval training or continuous training, which is moderate in intensity, effectively eased disease motor symptoms by about 25% and reduced fatigue in adults with Parkinson’s disease taking part in a small study. These findings further emphasize the significance of exercise as a…
Nearly all people with Parkinson’s disease taking part in Medtronic‘s ADAPT-PD trial had symptom-related brain signals strong enough to trigger adaptive deep brain stimulation (DBS), known for short as aDBS, according to early data. Among the findings: that results were similar regardless of disease severity or the location…
A new method for detecting toxic protein clumps of alpha-synuclein in skin cells may help diagnose Parkinson’s disease up to two decades before motor symptoms appear, according to a recent study. The novel technology combines super-resolution microscopy and advanced computational analysis to precisely map the protein clumps’ molecules…
Researchers have identified a mechanism underlying an addiction-like psychiatric complication of levodopa treatment known as dopamine dysregulation syndrome (DDS) in people with Parkinson’s disease in a recent preclinical study. In a mouse model, a DDS-like state was associated with abnormal activation of a certain population of nerve cells…
Subcutaneous, or under-the-skin, injections of COYA 302, a combination therapy in development by Coya Therapeutics, were found to reduce excessive inflammation and immune cell activation in a mouse model of Parkinson’s disease. These beneficial effects were observed in the nigrostriatal pathway, a brain circuit responsible for motor control,…
About 1 in 5 people with Parkinson’s disease in Italy have a family history of the disorder when the analysis extends beyond first-degree relatives to second- and third-degree relatives, a large-scale study has shown. First-degree relatives are comprise parents, siblings, and children. Second-degree relatives are aunts, uncles, grandparents, grandchildren,…
People with rare genetic mutations associated with Parkinson’s disease have a more than three times greater risk of developing amyotrophic lateral sclerosis (ALS), a neurodegenerative disorder that leads to progressive muscle weakness, than do those without the genetic variants. That’s according to new research, presented at the…
Get regular updates to your inbox.